Foot News and Research

RSS

iWalk announces availability of BiOM bionic lower limb system for above-knee amputees

iWalk, the personal bionics company advancing technology to restore natural movement for lower-limb amputees, today announced the availability of its BiOM bionic lower limb system for above-knee amputees.

13 Jun 2012

Experimental drug and genetic differences indicate how people deal with fear and stress

Researchers at Duke University and the National Institutes of Health have found a way to calm the fears of anxious mice with a drug that alters their brain chemistry. They've also found that human genetic differences related to the same brain chemistry influence how well people cope with fear and stress.

12 Jun 2012

Vibrating device aids diabetic neuropathy foot screening

A small disposable vibrating device may help detect peripheral sensory neuropathy in patients with diabetes, say UK researchers who believe the gadget could replace tuning fork screening.

8 Jun 2012

Battle to control malaria in Cambodia 'not over'

"Two years after some $22 million in donor funds were pumped into malaria control along the Cambodia-Thailand border to fight off suspected resistance to treatment, health workers say the battle is not over," IRIN reports, adding, "The government reported 103,000 malaria infections and 151 deaths nationwide in 2010.

8 Jun 2012

UCSF's ACT program helps amputees reach their athletic goals

Carlos Gonzalez stands out from an athletic group gathered on a grassy field at the UCSF Mission Bay campus. The gregarious 32-year-old sports a stylish fauxhawk and walks with a confident yet understated swagger. He's training to become a mixed martial arts (MMA) fighter.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.

4 Jun 2012

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

4 Jun 2012

HealthSouth to build comprehensive physical rehabilitation hospital in greater Orlando

HealthSouth Corporation today announced it has received permission from the state to proceed with building a comprehensive physical rehabilitation hospital in the greater Orlando, Fla., market. The 50-bed hospital will provide comprehensive physical rehabilitation to patients who have experienced stroke, trauma, brain and orthopedic injuries or other major illness or injuries.

2 Jun 2012

FDA approves RBI’s AppliGel-G for human testing

Royer Biomedical, Inc. (RBI) received FDA approval to proceed with Human Testing of AppliGel-G (Gentamicin) in management of Diabetic Foot Ulcers.

1 Jun 2012

State roundup: The effects of proposed Calif. budget cuts; Fewer free vaccinations in Texas

Low-income children in rural California communities are in jeopardy of losing their doctors and health care plans under Gov. Jerry Brown's budget proposal, state lawmakers, doctors and health advocates say. The governor is proposing to transfer nearly 900,000 children enrolled in Healthy Families, the state's Children's Health Insurance Program, to Medi-Cal – a program aimed at serving the state's poorest families, seniors and disabled residents.

30 May 2012

AHF's 'Condom-Nation' tour

“This tour is a national call to action to achieve these goals and we are delighted to be working with our three partner agencies in Chicago this weekend.”

28 May 2012

Clinilabs opens second Phase I unit in Southern New Jersey

Clinilabs, an early phase and specialty CRO that provides clinical drug development services to the pharmaceutical industry, today announced that they have opened a second Phase I unit in Southern New Jersey.

28 May 2012

New medicine can start and hasten healing of diabetic and other chronic sores

A unique new medicine that can start and hasten healing of diabetic and other chronic sores is being developed at Umeå University in Sweden. After several years of successful experimental research, it is now ready for clinical testing.

28 May 2012

UCSF receives $20M Sandler Foundation gift for neuroscience research and care

UCSF has received a challenge gift of $20 million from the Sandler Foundation that will provide major support for the university's groundbreaking research and clinical care efforts regarding neurological diseases.

25 May 2012

PERK protein necessary to maintain behavioral flexibility

Researchers have identified a protein necessary to maintain behavioral flexibility, which allows us to modify our behaviors to adjust to circumstances that are similar, but not identical, to previous experiences. Their findings, which appear in the journal Cell Reports, may offer new insights into addressing autism and schizophrenia—afflictions marked by impaired behavioral flexibility.

25 May 2012

NYULMC opens new 327,000 square-foot Ambulatory Care Center

As part of its plan to expand access to a wide array of outpatient services, NYU Langone Medical Center has opened a new 327,000 square-foot Ambulatory Care Center (ACC) at 240 East 38th Street.

24 May 2012

Proper care of diabetic foot infections can save limbs, lives

Diabetic foot infections are an increasingly common problem, but proper care can save limbs and, ultimately, lives, suggest new guidelines released by the Infectious Diseases Society of America.

23 May 2012

Scientists determine genetic sequences of all 12 vancomycin-resistant staph strains

National Institutes of Health-funded scientists have determined the genetic sequences of all 12 available strains of Staphylococcus aureus bacteria resistant to vancomycin-an antibiotic of last resort-and have demonstrated that resistance arose independently in each strain after it acquired a specific bit of genetic material called transposon Tn1546

23 May 2012

More than 16,000 patients visit NYU Langone's new CMC

If the first month at NYU Langone's new Center for Musculoskeletal Care (CMC) is any indication of the growing need for integrated care, the more than 16,000 patients coming to the facility on 38th Street in Manhattan since it opened in April is a true testament.

22 May 2012